Product Description
A monospecific hexamer-forming antibody, based on the HexaBody technology platform, directed against the cell surface antigen CD27, with potential immunostimulatory and antineoplastic activities. Upon administration, anti-CD27 monoclonal antibody GEN1053/BNT313 targets and binds to CD27 expressed on a variety of immune cell types, including most T lymphocytes, and forming a hexamer upon binding. This induces CD27-mediated signaling, and enhances CD27-mediated responses, including the expansion of antigen-activated T cells and natural killer (NK) cells. This restores immune function and leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. CD27, a co-stimulatory molecule and member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on T lymphocytes, memory B cells and NK cells. It plays an important role in NK cell-mediated cytolytic activity and T- and B-lymphocyte proliferation and activation. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-cd27-monoclonal-antibody-gen1053-bnt313)
Mechanisms of Action: CD27 Agonist
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Genmab
Company Location: 1253 COPENHAGEN K G7 00000
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Spain
Active Clinical Trial Count: 2
Highest Development Phases
Phase 2: Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2021-006692-42 | P2 |
Active, not recruiting |
Oncology Solid Tumor Unspecified |
2027-07-15 |
|
| GCT1053-01 | P2 |
Completed |
Oncology Solid Tumor Unspecified |
2024-05-23 |